Exelixis, Inc. (NASDAQ:EXEL) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026.
On March 2, 2026, Exelixis, Inc. (NASDAQ:EXEL) saw its price target from RBC Capital lowered from $46 to $43. The firm’s Sector Perform rating was maintained on the stock. In a research note, RBC Capital pointed out that after the reporting of the data from the HIF-2alpha inhibitors study by Exelixis, Inc. (NASDAQ:EXEL)’s competitor Merck (MRK), the share value of the company will potentially witness a decline in the range of 5% to 10%, owing to competitive pressures.
Separately, H.C. Wainwright raised its price target on Exelixis, Inc. (NASDAQ:EXEL) from $52 to $54 while maintaining a Buy rating on February 12, 2026. Analysts updated their model following the reporting of the results for the fourth quarter of 2025.
As of March 25, 2026, Exelixis, Inc. (NASDAQ:EXEL) maintains a Buy rating from 45% of 22 analysts followed by CNN, with a 1-year average upside potential of 15.47%.
Founded in 1994, Exelixis, Inc. (NASDAQ:EXEL) is a leading oncology-focused biotechnology company with headquarters in California. The company specializes in discovering and commercializing next-generation medicines like CABOMETYX to treat difficult-to-treat cancers.
While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Space Exploration Stocks to Buy According to Analysts and 10 Best Diagnostics and Research Stocks to Buy According to Analysts
Disclosure: None. Follow Insider Monkey on Google News.
